

January 28, 2016



Poxel Provides YE15 Cash and Turnover Figures

LYON, France--(BUSINESS WIRE)-- Regulatory News:

POXEL SA (Paris:POXEL) (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, today announced its cash position and its turnover for the fiscal year 2015.

As of December 31st, 2015, the cash and cash equivalents amounted to €42.4 million* compared to €10.3 million on December 31st, 2014.

The 2015 revenues resulting from collaboration, licensing and other agreements amounted €60,000.

These figures are consistent with the Company's expectations and its growth strategy, which remains focused on the clinical development of its diabetes drug candidates Imeglimin and PXL770.

*unaudited

Next financial press release: Year Full-Year Financial Statement, March 31st, 2015

About Poxel

Poxel uses its unique development expertise in metabolism to advance a pipeline of truly novel products currently focused on type 2 diabetes. Our first-in-class lead product, Imeglimin, targeting mitochondrial dysfunction, has successfully completed Phase 2 development in the US and EU and has entered clinical development in Japan. We are advancing our second program, PXL770, a direct AMPK activator, through clinical proof-of-concept. We will generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxel.com)

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20160128005875/en/>

Investor relations / Media - EU/US

MacDougall Biomedical Communications

Gretchen Schweitzer or Stephanie May, + 49 89 2424 3494 or + 49 172 861 8540

smay@macbiocom.com

or

Investor relations / Media - France

NewCap
Florent Alba/Nicolas Mérieau
+ 33 1 44 71 98 55
poxel@newcap.fr

Source: Poxel